Log in with your email address username.


[Comment] Daratumumab in multiple myeloma

It is easy to be overwhelmed by hype in cancer research, with promising new discoveries often portrayed as so-called game changers.1 Most new treatments for cancer are far from being transformative, but daratumumab is possibly a rare exception. It targets CD38, an antigen that is uniformly expressed in myeloma cells.2 As the most anticipated new drug in multiple myeloma in more than a decade, daratumumab has all the features that are necessary to make a substantive difference in a devastating cancer, which—despite many advances—manages to outwit all available treatments over time: a novel mechanism of action, single-agent activity, non-cross resistance, and safety.